Malaria Information and Prophylaxis, by Country [I]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Iceland None Not Applicable Not Applicable Not Applicable
India All areas throughout country, including cities of Bombay (Mumbai) and Delhi, except none in areas > 2,000 m (6,562 ft) in Himachal Pradesh, Jammu and Kashmir, and Sikkim. Chloroquine P. vivax 50%,

P. falciparum >40%,

P. malariae and P. ovale rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Indonesia All areas of eastern Indonesia (provinces of Maluku, Maluku Utara, Nusa Tenggara Timur, Papua, and Papua Barat), including the town of Labuan Bajo and Komodo Islands in the Nusa Tengarra region. Rural areas of Kalimantan (Borneo), Nusa Tenggara Barat (includes the island of Lombok), Sulawesi, and Sumatra.

Low transmission in rural areas of Java, including Pangandaran, Sukabumi, and Ujung Kulong.

None in the cities of Jakarta and Ubud, resort areas of Bali and Java, and Gili Islands and the Thousand Islands (Pulau Seribu).

Chloroquine (P. falciparum and P. vivax) P. falciparum 57%, P. vivax 43%,
P. knowlesi,
P. malariae,
P. ovale
rare
Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Iran March-November in rural areas of Fars Province, Sistan-Baluchestan Province, and southern, tropical parts of Hormozgan and Kerman Provinces. Chloroquine P. vivax 93%,

P. falciparum 7%

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Iraq None Not Applicable Not Applicable Not Applicable
Ireland None Not Applicable Not Applicable Not Applicable
Israel None Not Applicable Not Applicable Not Applicable
Italy including Holy See (Vatican City) None Not Applicable Not Applicable Not Applicable

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
6. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.

Page last reviewed: June 26, 2019